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Background/aim: Acute pancreatitis is a clinical picture with a wide range of symptoms from mild inflammation to multiorgan failure
and death. The aim of this study is to investigate the effects of Adalimumab (ADA) on inflammation and apoptosis in a cerulein-induced
acute pancreatitis model in rats.
Material and methods: Experimental cerulein-induced acute pancreatitis model was created by applying 4 intraperitoneal cerulein
injections at 1-h intervals. A total of 40 rats, 8 in each group, were randomly distributed into five groups. In the groups that ADA
treatment was given, two different doses of ADA were administered 5 mg/kg and 20 mg/kg as low and high doses, respectively. The rats
were sacrificed 12 h after the last intraperitoneal administration of ADA. Blood samples were obtained from each rat for amylase, IL-6,
and IL-1β measurements. Hematoxylin and Eosin (H&E) stains were used to undertake the histopathological analysis of the pancreas.
The terminal deoxynucleotidyl transferase-mediated nick-end-labeling (TUNEL) method was used to evaluate apoptosis.
Results: Plasma amylase, IL-6, and IL-1β levels were significantly elevated in acute pancreatitis groups (p < 0.05). It was determined that
both low (5 mg/kg) and high doses (20 mg/kg) of ADA ameliorated the parameters (plasma amylase, IL-6, and IL-1β) (p < 0.05). Although
significant improvements were detected in the Schoenberg scoring system and the apoptotic index from the TUNEL method after highdose ADA treatment, no significant amelioration was observed in the histopathological examinations in the low-dose ADA group.
Conclusions: It has been determined that the administration of high-dose ADA effectively alleviated the symptoms of acute pancreatitis
and reduced the level of apoptosis. In line with the findings of our study, we have predicted that high-dose (20 mg/kg) ADA can be used
as an effective and safe drug in the treatment of patients with acute pancreatitis.
Key words: Acute pancreatitis, Adalimumab, inflammation, apoptosis

1. Introduction
Acute pancreatitis (AP) constitutes an important part
of the indications for emergency hospitalization in
gastroenterology and internal medicine clinics all over
the world [1]. AP is an acute and severe inflammation
of the pancreas that develops due to various factors [2].
Mild abdominal pain is among the possible symptoms.
However, it is a process with an increased inflammatory
response that often manifests itself with acute, severe
abdominal pain and accompanying elevated pancreatic
enzymes (amylase, lipase) [3]. Despite recent advances
in gastroenterology, AP is still strongly linked to
morbidity, mortality, and utilization of healthcare
resources [4]. AP has a 1.5% mortality rate in mild

cases. This rate rises to 17% in severe cases [5,6]. Bile
duct diseases (like gallstones) and alcohol use constitute
most of the etiology of AP. In the pathogenesis of AP,
there is a complex series of immunological responses
that affect the course of the disease. Regardless of the
cause that initiates the response, this locally initiated
inflammatory response may become widespread and
cause multi-organ damage [7]. Autodigestion caused
by digestive enzymes released from pancreatic acinar
cells is the primary trigger of local inflammation. This
autodigestion spreads to the retroperitoneal sites over
time, creating widespread necrotic areas. These necrotic
tissues trigger infection over time, causing sepsis and
multiple organ damage [8].
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Cerulein is an oligopeptide consisting of 10 amino acids.
It was first obtained from the skins of Australian green frogs.
It is very similar in structure to cholecystokinin. Therefore,
it triggers pancreatitis in experimental animal models
with a mechanism similar to pancreatic autodigestion [9].
Cerulein, in addition to triggering inflammation in acinar
cells, causes dysregulation in pancreatic digestive enzyme
production. It causes acinar cell death and pancreatic
edema. Cerulein also causes the activation of NADPH
oxidase, a source of reactive oxygen species that contribute
to inflammation, and Janus kinase, which is another
trigger of inflammation [10]. In this study, intraperitoneal
cerulein was used to create pancreatitis in rat models.
It has been known for many years that proinflammatory
cytokines are involved in the physiopathology of AP.
TNF (tumor necrosis factor)-α, ICAM-1, interleukin
(IL)-1, IL-6, IL-8, platelet-activating factor (PAF), and
MCP (monocyte chemoattractant protein)-1 are proinflammatory mediators that play a role in AP [7]. TNFis a cytokine produced by macrophages and lymphocytes.
In previous studies, TNF-α was found to be increased
in patients with pancreatitis and in animal models [11–
13]. Recombinant human IgG1 monoclonal antibody
Adalimumab (ADA) specifically targets human TNF-α.
ADA inhibits both superficial cell receptors of TNF-α,
type-I (p55), and type-II (p75). Because of this effect,
ADA is a treatment that has been approved for psoriasis,
psoriatic arthritis, and rheumatoid arthritis for years. In
recent studies, it has been shown that TNF-α inhibition
in experimental animal models is beneficial in AP [14,15].
In a study conducted on rats in 2010, the effects of ADA
in (Na)-taurocholate-induced pancreatitis were evaluated.
The beneficial effects of ADA at a dose of 50mg/kg on
pancreatitis have been demonstrated histopathologically
and biochemically [16].
In this study, it is aimed to examine the effects of ADA,
which we predict can be used as a new therapeutic agent
in acute pancreatitis that still has no curative treatment,
on inflammation and apoptosis in an experimental acute
pancreatitis model.
2. Materials and methods
2.1. Study design
In this study, 40 Spraque-Dawley rats (250–350 g) were
used. These rats were kept in cages at approximately 24 °C
in 12-h day-night cycle. The rats were allowed free water
and food, and their food intake was stopped 12 h before
injections. The study was carried out within the framework
of national guidelines for the care and use of laboratory
animals. After obtaining approval from the University
of Health Sciences Hamidiye Experimental Animals
Ethics Committee, the experimental procedures were
performed in the University of Health Sciences Hamidiye
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Medical Faculty Experimental Animals Laboratory. Acute
pancreatitis was induced by intraperitoneal injection
of cerulein (Sigma, St. Louis, MO, USA) administered 4
times at 1-h intervals.
A total of 40 rats, 8 rats in each group, were randomly
distributed into five groups.
Group 1: Sham group (1mL of saline was administered
to rats 4 times intraperitoneal injection at 1-h intervals,
rats were sacrificed 24 h after the last injection).
Group 2: Acute pancreatitis (AP) group (intraperitoneal
injection of 40 μg/kg cerulein in saline 4 times at 1-h
intervals. Rats were sacrificed 24 h after the last injection).
Group 3: AP + low-dose ADA group (intraperitoneal
injection of 40 μg/kg cerulein in saline 4 times at 1-h
intervals, then a single dose intraperitoneal injection of
5 mg/kg ADA 12 h after the last cerulein injection. The
rats in this group were sacrificed 12 h after the last ADA
injection).
Group 4: AP + high-dose ADA group (intraperitoneal
injection of 40 μg/kg cerulein in saline 4 times at 1-h
intervals, then a single dose intraperitoneal injection of
20 mg/kg ADA 12 h after the last cerulein injection. The
rats in this group were sacrificed 12 h after the last ADA
injection).
Group 5: Placebo group (intraperitoneal injection of
40 μg/kg cerulein in saline 4 times at 1-h intervals, then
intraperitoneal injection of 1 cc saline as placebo 12 h
after the last cerulein injection. The rats in this group were
sacrificed 12 h after saline administration).
2.2. Randomized controlled trials
Randomization is a process used to ensure that each
experimental unit has an equal probability of receiving
a particular treatment. An experiment with 5 treatment
groups (1: Sham, 2: Pancreatitis 3: Adalimumab 5 mg/kg
4: Adalimumab 10 mg/kg, and 5: Placebo) with 8 animals
per group. The function = Rand () in Excel can be used
to generate a column of random numbers in column A.
Column B would contain eight 1’s, eight 2’s, eight 3’s,
eight 4’s and eight 5’s for each of the treatment groups and
column C would contain unique identification numbers
for each of the 40 animals. Sorting columns A and B by
the order of column A will randomize the order of column
B and each animal of column C will be allocated into
treatment 1, 2, 3, 4, or 5 at random.
The number of samples to be taken for the study was
determined by GPOWER 3.1.9.4. Statistically, a total of 40
rat plans were calculated with 0.85 power 0.05 error 0.065
effect size files. Amylase (U/l) values for 5 groups for effect
size.
Blood samples were collected by intracardiac route
from the rats. The pancreas tissues were then quickly
removed, and the rats were euthanized with highdose anesthesia. Then blood samples of animals were
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centrifuged for 10 min at 3500 rpm and the plasma samples
were stored at –80 °C until analyses. Amylase, IL-1β, and
IL-6 levels were measured in plasma samples. Commercial
enzyme-linked immunosorbent assay (ELISA) kits were
used to determine the plasma amylase (Scientific Research
Special Hangzhou Eastbiopharm Co. Ltd. Hangzhou),
IL-6 (Scientific Research Special Hangzhou Eastbiopharm
Co. Ltd. Hangzhou), and IL-1β (AssayPro, USA) levels.
Analyses were carried out according to the instructions
and guidelines of manufacturers. Pancreatic tissue samples
of rats were fixed in 10% formaldehyde. Preparations were
stained with hematoxylin and eosin (H&E). They were
cut into 5 μm-thick sections stained with hematoxylin
and eosin. Samples were numbered from one to forty. The
pathologist was not informed about the treatments given
for blind evaluation. Edema, acinar necrosis, bleeding,
inflammation, and the presence of perivascular infiltration
were examined and evaluated under a photomicroscope
(Olympus BX 51; Tokyo, Japan) according to the
Schoenberg grading system. It was graded between 0 and

4 according to the Schoenberg grading system (Figure 1)
[17]. Terminal deoxynucleotidyl transferase-mediated
nick-end-labeling (TUNEL) method was used to examine
apoptotic cells and for examination, a commercial kit
(ApopTag Plus Peroxidase, In Situ Apoptosis Detection
Kit, Chemicon Int., Temecula, CA) was used. The nuclei
are expected to be blue in normal cells from pancreatic
samples prepared with the TUNEL technique. The nuclei
of apoptotic cells appear brown. The percentages of
apoptotic cells were calculated according to the number
of cells in the area where the acinar cells were most heavily
stained (Figure 2).
2.3. Statistical analysis
Statistical evaluation was performed with the Statistical
Package for Social Sciences (SPSS 20.0 for windows). The
conformity of the data to the normal distribution was
checked with the Shapiro-Wilk test, and the homogeneity
of the variances was checked with the Levene test. The
results were expressed as Mean ± SD or Median (minmax). Comparisons of means between groups were

Figure 1. Hematoxylin and eosin staining of pancreatic tissue samples.
A. Control group with normal pancreatic tissue, 20× magnification.
B. Acute pancreatitis group, intralobular polymorphonuclear cell infiltration, vacuolation, necrosis and edema are
seen, 20x magnification.
C. Sp treated placebo group, vacuolization, edema, and inflammation are still existing, 20× magnification.
D. Adalimumab treatment group, reduced polymorphonuclear cells, vacuolation, and edema with low dose, 20×
magnification.
E. Adalimumab treatment group with high dose, 20× magnification.
(Polymorphonuclear cell infiltration, vacuolation, necrosis, and edema are marked with black arrows)
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Figure 2. TUNEL technique shows the apoptotic status of study groups.
A. Control group. No apoptotic cell is seen.
B. Acute pancreatitis group. Increased apoptotic cells are seen. Apoptotic index is 4.7%.
C. Sp treated placebo group, similar features with acute pancreatitis group. Apoptotic index is 5.3%.
D. Adalimumab treatment group. Decreased apoptotic cells are seen with a low dose. Apoptotic index is 3.55%
E. Adalimumab treatment group. Apoptotic index is 2.08%
(TUNEL staining, ×20 magnification. Apoptotic cells are marked with black arrows).

evaluated with one-way analysis of variance (ANOVA)
(Post Hoc: Bonferonni) for normally distributed data and
the Kruskal-Wallis test (Post Hoc: Mann-Whitney U test
with Bonferroni correction) for nonparametric data. p <
0.05 and p < 0.005 (Bonferroni correction) were considered
as statistically significant and two-sided tests were applied.
3. Results
3.1. Biochemical examination
Plasma amylase, IL-6, and IL-1β levels were examined
according to the instructions of the ELISA kit
manufacturer (AssayPro, USA, Bioscience, Austria and
Scientific Research Private Hangzhou Eastbiopharm Co.
Ltd. Hangzhou, repeatedly). Results are shown in Table
1. Plasma amylase, IL-6, and IL-1β levels in the groups
with acute pancreatitis were significantly increased when
compared to the sham group (p < 0.01). Pancreatitis control
(Group 2) and pancreatitis placebo (Group 5) groups did
not differ statistically. On the other hand, plasma amylase
level, IL-6, and IL-1β levels were significantly decreased in
the ADA-treated groups (Groups 3 and 4) compared to the
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control group (p < 0.05). When the groups receiving lowdose ADA (Group 3) and high-dose ADA (Group 4) were
compared, no significant difference was found between
the two groups (Table 2).
3.2. Histopathological evaluation
For histopathological evaluation, pancreatic tissue
samples were fixed using 10% buffered formaldehyde and
embedded in paraffin. Tissue sections were stained with
hematoxylin and eosin (H&E) and taken for examination
under a photomicroscope (Olympus BX 51; Tokyo,
Japan). Damages in tissues were classified by applying the
Schoenberg grading system.
Significant edema, inflammation, vacuolization, and
fat necrosis were detected in all cerulein injected groups
compared to the sham group (Table 3). There was no
significant improvement in pancreatitis control and
pancreatitis placebo groups in the low-dose ADA group
(Group 3). However, a significant improvement was
found in the group receiving high-dose ADA (Group 4)
compared to all groups with pancreatitis (p < 0.01) (Table
4). A commercial kit (ApopTag Plus Peroxidase, In Situ
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Table 1. The biochemical parameters of the study groups.
Groups

Amylase (U/L)

Il-6 (pg/mL)

IL-1β (pg/mL)

Group 1

77.28 (63–98)

28.76 (22–52)

33.5 (20–58)

Group 2

477.13 (401–611)

605.08 (579–670)

145.62 (128–171)

Group 3

279.65 (221–360)

515.45 (431–590)

114.88 (81–130)

Group 4

225.48 (215–270)

404.5 (301–528)

77.28 (63–93)

Group 5

479.32 (421–610)

774.96 (725–866)

152.53 (101–170)

p

<0.0001

<0.0001

<0.0001KW

KW

KW

Data are given as median (min-max). KW: Kruskal Wallis
Table 2. Statistical parameters of the study groups.
Groups

Amylase (U/L)

IL-6 (pg/mL)

IL-1β (pg/mL)

Groups 1–2

p < 0.01

p < 0.01

p < 0.01

Groups 1–3

p < 0.01

p < 0.01

p < 0.01

Groups 1–4

p < 0.01

p < 0.01

p < 0.01

Groups 1–5

p < 0.01

p < 0.01

p < 0.01

Groups 2–3

p < 0.01

p < 0.05

p < 0.05

Groups 2–4

p < 0.01

p < 0.01

p < 0.05

Groups 2–5

NS

NS

NS

Groups 3–4

NS

NS

NS

Groups 3–5

p < 0.01

p < 0.05

p < 0.05

Groups 4–5

p < 0.01

p < 0.01

p < 0.01

Abbreviation: NS: Not significant. Mann-Whitney U test with Bonferroni correction multiple comparison. The mean
difference is significant at the p < 0.05 level and p < 0.005 is considered statistically significant after Bonferroni’s
correction.
Table 3. Schoenberg scores of the study groups.
Groups

Edema

Inflammation

Vacuolation

Necrosis

Score

Group 1 (Sham)

0

0

0

0

0

Group 2 (Pancreatitis)

3.25 ± 0.5

3.00

2.75 ± 0.5

3 ± 0.81

12 ± 0.81

Group 3 (Adalimumab 5 mg/kg)

3.28 ± 0.48

2.57 ± 0.53

2.14 ± 0.69

2.85 ± 0.69

10.85 ± 1.67

Group 4 (Adalimumab 10 mg/kg) 2.28 ± 0.48

1.57 ± 0.78

1 ± 0.57

1.14 ± 0.37

6 ± 1.15

Group 5 (Placebo)

3.75 ± 0.5

3 ± 0.81

2.75 ± 0.5

2.75 ± 0.5

12.25 ± 1.70

P

0.005A

<0.00001A

0.007A

0.0009A

<0.00001A

A: One-way analysis of variance (ANOVA)

Apoptosis Detection Kit, Chemicon Int., Temecula, CA)
was used to evaluate apoptosis in pancreatic tissues with
TUNEL method. Apoptotic indices were found to be
4.7% and 5.3% in the pancreatitis control group (Group
2) and the placebo group (Group 5), respectively. The

apoptosis index was 3.55% in the group that received lowdose ADA (Group 2) with a minimal decrease (Table 5).
However, in the group receiving high-dose ADA (Group
5), the apoptosis index was 1.84% which was a marker of
significant improvement.
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Table 4. Statistical Schoenberg scores of the study groups.
Groups

Schoenberg scores*

Groups 1–2

p < 0.001

Groups 1–3

p < 0.001

Groups 1–4

p < 0.001

Groups 1–5

p < 0.001

Groups 2–3

NS

Groups 2–4

p < 0.001

Groups 2–5

NS

Groups 3–4

p < 0.01

Groups 3–5

NS

Groups 4–5

p < 0.05

Abbreviation: NS: Not significant, Bonferroni, multiple comparison. *The mean
difference is significant at the 0.05 level considered statistically significant.
Table 5. Apoptotic scores.
Groups

Apoptotic scores

Group 2

4.70%

Group 3

3.55%

Group 4

1.84%

Group 5

5.30%

4. Discussion
Proinflammatory cytokines are the most prominent
factors in the pathogenesis of local and systemic effects of
acute pancreatitis. There is a serious correlation between
the presence of an increased proinflammatory cytokine
response in the early phase of the disease, the inadequacy
of the corresponding antiinflammatory response, and the
severity of the disease [18]. Through the activation and
adherence of inflammatory cells, the release of cytokines,
nitric oxide (NO), and inflammatory mediators, TNF-α is
known to mediate tissue injury. Neutrophils activated by
TNF-α release free radicals, causing diffuse tissue edema,
lipid peroxidation, and ultimately cell death [19,20]. The
search for a new treatment that can change the course of
acute pancreatitis is still ongoing. It has been predicted that
TNF-alpha inhibition may affect the course of the disease by
suppressing local and systemic inflammation. Some studies
have also been done on experimental animal models before
[12,13]. Adalimumab is a TNF-α inhibitor used in clinical
practice in the treatment of many diseases such as psoriasis,
psoriatic arthritis, rheumatoid arthritis, ankylosing
spondylitis, inflammatory bowel diseases (Crohn’s disease
and ulcerative colitis), and juvenile idiopathic arthritis [21].
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Yilmaz et al. showed the beneficial effects of ADA
at a dose of 50 mg/kg on sodium taurocholate-induced
pancreatitis in rats [16]. In this study, it was observed
both biochemical and histopathological improvements
in pancreatitis at a dose of 20 mg/kg. Grewalet et al.
stated that TNF-α levels increased in acute pancreatitis
and this cytokine may play a role in the pathogenesis of
the disease. Researchers demonstrated that a statistically
significant improvement in biochemical parameters
was achieved by using polyclonal blockade of TNF-α
[12]. Hughes et al. showed that anti-TNF antibodies are
beneficial in curing acute pancreatitis and its related
complications in rats [13]. Norman et al., using a soluble
antagonist of the type I TNF receptor (TNFbp), reported
that it reduced the course and mortality of experimentally
induced pancreatitis [22]. In this study, it was found
that inflammation was suppressed better, and apoptosis
was lower in the high-dose ADA treatment group. It is
obvious that ADA, which is quite safe in terms of its side
effect profile, will be more effective in the treatment of
acute pancreatitis at higher doses. However, the results of
the study cannot be directly applied to humans without
human studies.

ÇAKIR GÜNEY et al. / Turk J Med Sci
5. Conclusion
Our study shows that ADA is a new alternative in the
treatment of AP with suitable doses. Our study predicts
that ADA, which is used in daily practice in many diseases,
can be used in the treatment of pancreatitis. If AP is not
treated urgently, its acute and chronic effects can have lifethreatening consequences. For this reason, it is obvious
that there is a need for new treatment alternatives for
pancreatitis which has limited treatment options. ADA
may be an effective and correct treatment option in
patients with acute pancreatitis. However, more human
studies are needed to evaluate the effectiveness of ADA in

people with acute pancreatitis. Studies on this subject in
new and larger series are required.
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